Inscripta raises additional $20 million in Series C financing round
Category: #health  By Nikita Chaurasia  Date: 2019-04-06
  • share
  • Twitter
  • Facebook
  • LinkedIn

Inscripta raises additional $20 million in Series C financing round

Inscripta is working to develop a full suite of gene-editing tools (reagents, software and instruments) to increase the efficiency and speed of CRISPR-based gene-editing

The US-based gene-editing technology company Inscripta has announced that it has raised additional $20 million in its previously declared Series C financing. The new funding, which comes from existing investors, adds to the $85.5 million financing that the company announced in 2018. The total amount raised now stands at $105.5 million.

According to the press release by Inscripta, the existing investors are Foresite, MLS Capital, Venrock, NanoDimension, Paladin Capital Group and Mérieux Développement. Inscripta is working to develop a full suite of gene-editing tools (reagents, software and instruments) to increase the efficiency and speed of CRISPR-based gene-editing.

The tools being developed by Inscripta include CRISPR enzyme family, called MADzymes; custom nucleases for commercial partners and researchers; and a full suite of gene-editing tools (reagents, software and instruments).

John Stuelpnagel, Chairman, Board of Directors, Inscripta, has reportedly said that researchers need a scale transformation to make gene editing efforts more useful and informative.

Reportedly, Inscripta had announced the broad adoption of MAD7 in December 2018. MAD7 is a proprietary CRISPR enzyme which has been offered to academic and commercial researchers without any upfront licensing fees or “reach-through royalties” on discoveries made using the technology.

For the record, MADzymes have different cut efficiencies, different PAM recognition sequences, different enzyme kinetics and reduced sizes. The first enzyme MAD7’s gene editing systems were patented recently. The enzyme is reportedly effective in microbial as well as mammalian systems. The robust editing activities have been shown by MAD7 in prokaryotic as well as eukaryotic microbes.

For the uninitiated, Colorado-based Inscripta is a gene-editing technology company which creates tools to revolutionize human life. The company works to provide control to researchers for cutting edge, single cell engineering.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Scientists say COVID-19 is airborne, ask WHO to revise recommendations
Scientists say COVID-19 is airborne, ask WHO to revise recommendations
By Nikita Chaurasia

Numerous scientists across the globe have reportedly sent an open letter to WHO (World Health Organization) seeking the health agency to revise recommendations regarding the novel coronavirus. As per credible reports, around 239 scientists from 32 c...

Hyderabad gains second Oracle cloud data center after Mumbai
Hyderabad gains second Oracle cloud data center after Mumbai
By Nikita Chaurasia

American multinational computer technology corporation, Oracle has recently made it to the headlines post launching its second cloud data center in Hyderabad in a bid to support increased cloud services demand. For those uninitiated, Oracle launched...

HSA: Banned substances found in two weight loss products online
HSA: Banned substances found in two weight loss products online
By Nikita Chaurasia

HSA (The Health Sciences Authority of Singapore) has reportedly issued an alert regarding two weight loss products found online which comprise of banned substances and can be harmful to the human health. The agency has revealed that the two products ...